QLI: Koefisien rega marang pendapatan Qilian International Holding Group Limited
Qilian International operations are restricted by strict FDA medical regulations regarding the disposal of biomaterials. The price-to-sales trend clearly demonstrates the business's resilience to shocks, with the indicator reaching 4.20. The growth of biologics is driven by synergy with Chinese agricultural holdings, although trade wars with the US create risks of Western capital blockages and more stringent quality audits.
Rincian metrik lan analitis perusahaan Qilian International Holding Group Limited (QLI)
- nilai pasar lan prakiraan target analis:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Qilian International|QLI - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Qilian International Corp|QLI - Gunggung utang perusahaan|Rasio utang marang aset resik Qilian International Holding Group Limited|QLI - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Qilian International|Rasio likuiditas darurat qlsyy.net
- rincian asil keuangan lan kelipatan valuasi:
QLI - Penghasilan resik|Bathi resik mangsa ngarep Qilian International|QLI - Pangali P/E|Rasio prakiraan rega marang bathi Qilian International Holding Group|QLI - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Qilian International Holding Group Limited|QLI - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Qilian International|QLI - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan qlsyy.net|QLI - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Qilian International
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:qlsyy.net, QLI
The price-to-sales ratio dynamics for Qilian International (QLI) on the GURU.Markets platform reflect the impact of drug portfolio diversification and raw material supply stability on the business's market valuation. This multiple, calculated as the ratio of market capitalization to annual revenue, determines whether the asset is overvalued or if the capital is undervalued relative to the company's actual operational cash flows.
Perusahaan pesaing
haleon.com (HLN) - Multiplikator rega marang pendapatan|Multiplikator P/S KVUE (Kenvue)|Koefisien rega marang pendapatan Verona Pharma PLC (VRNA)|MENS - Rasio rega marang pendapatan|LGND: Rasio rega marang pendapatan|AMRX: Multiplikator P/S|PRGO - Koefisien rega marang pendapatan|ALVO (Alvotech SA) - Multiplikator P/S|Multiplikator P/S Liquidia Corp|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANI Pharmaceuticals Corp - Rasio kapitalisasi marang pendapatan|MannKind Corporation - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan AMPH|Pacira BioSciences, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan ARS Pharmaceuticals Inc SPRY|Theravance (TBPH) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan AQST|Kapitalisasi marang pendapatan SCPH|TECX (Tectonic) - Kapitalisasi marang volume dodolan|Multiplikator P/S TNXP|SXTC - Rega marang dodolan|Rasio rega marang pendapatan Eupraxia Pharmaceuticals Inc. EPRX|Rasio kapitalisasi pasar marang pendapatan BHST|EXOZ - Rasio rega marang pendapatan|ORMP (Oramed Pharmaceuticals) - Rasio kapitalisasi marang pendapatan|ENTX: Multiplikator P/S|MindWalk Holdings, Inc. (HYFT) - Multiplikator P/S|Kapitalisasi marang pendapatan ABVC|CPIX (Cumberland Corp) - Kapitalisasi marang volume dodolan|Multiplikator P/S QNTM|Koefisien rega marang pendapatan fibrogen.com|Rasio rega marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings (RANI) - Rega marang dodolan|SNYR - Rasio rega marang pendapatan|RLYB (Rallybio Corporation) - Rasio kapitalisasi marang pendapatan|LEXX: Multiplikator P/S|pulmatrix.com (PULM) - Multiplikator P/S|Rasio rega marang pendapatan Pheton Holdings Limited|Rasio rega marang pendapatan APM|Rasio rega marang pendapatan Lyra Therapeutics, Inc (LYRA)|Impact BioMedical, Inc. (IBO) - Multiplikator rega marang pendapatan|Rasio rega marang pendapatan TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Rasio rega marang pendapatan|PainReform - Multiplikator P/S|Koefisien rega marang pendapatan Altamira Therapeutics CYTO|Lipella (LIPO) - Rasio rega marang pendapatan|Rasio rega marang dodolan OPTN (OptiNose Corp)|PIRS (Pieris Pharmaceuticals) - Multiplikator P/S|PROC: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S PTPI|Multiplikator P/S Acelyrin Inc. (SLRN)|Rasio rega marang pendapatan TFF Pharma TFFP
